DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Cristofanilli M, Turner NC, Bondarenko I. et al.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
The Lancet Oncology 2016;
17: 425-439
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.